Australian contract research organisation Molecule2Market has appointed Dr Julie Ince-Demetriou as its first Chief Executive Officer, marking a pivotal moment in the company’s evolution as it enters a new phase of growth and operational scale.
Molecule2Market appoints inaugural CEO to lead next phase of growth
February 10, 2026 Australian BiotechBioPharmaDispatch Executive
Latest Video
New Stories
-
BCEC partners with Life Sciences Queensland to launch bursary for next-gen bio innovation leaders
February 10, 2026 - - Australian Biotech -
Memphasys fast-tracks Australian market entry with early TGA approval for Felix system
February 10, 2026 - - Australian Biotech -
Algorae expands commercial footprint with new licensing deal
February 10, 2026 - - Australian Biotech -
Immutep reaches midpoint in global Phase 3 lung cancer trial
February 10, 2026 - - Australian Biotech -
Molecule2Market appoints inaugural CEO to lead next phase of growth
February 10, 2026 - - Australian Biotech -
ViiV invests in HIV-focused initiatives through Positive Action Community Grants program
February 9, 2026 - - Latest News -
A 'meeting of minds' and the risk of not being able to 'unknow' information
February 9, 2026 - - Latest News

